PharmaEngine Future Growth

Future criteria checks 1/6

PharmaEngine is forecast to grow earnings and revenue by 15.9% and 7.6% per annum respectively while EPS is expected to grow by 15.3% per annum.

Key information

15.9%

Earnings growth rate

15.3%

EPS growth rate

Biotechs earnings growth	37.2%
Revenue growth rate	7.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	02 May 2024

Recent future growth updates

Recent updates

Would PharmaEngine, Inc. (GTSM:4162) Be Valuable To Income Investors?

Mar 30

How Much Did PharmaEngine's(GTSM:4162) Shareholders Earn From Share Price Movements Over The Last Five Years?

Feb 18

Is PharmaEngine, Inc.'s (GTSM:4162) Stock On A Downtrend As A Result Of Its Poor Financials?

Jan 14

We're Not Counting On PharmaEngine (GTSM:4162) To Sustain Its Statutory Profitability

Dec 10

Earnings and Revenue Growth Forecasts

TPEX:4162 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	894	383	N/A	561	1
12/31/2024	845	361	N/A	571	1
12/31/2023	768	275	257	257	N/A
9/30/2023	739	291	217	218	N/A
6/30/2023	648	298	283	286	N/A
3/31/2023	649	303	225	229	N/A
12/31/2022	654	319	198	202	N/A
9/30/2022	700	377	260	264	N/A
6/30/2022	722	362	216	217	N/A
3/31/2022	713	447	301	301	N/A
12/31/2021	655	426	929	930	N/A
9/30/2021	1,237	837	829	829	N/A
6/30/2021	1,156	782	831	832	N/A
3/31/2021	1,088	631	713	713	N/A
12/31/2020	1,056	604	64	65	N/A
9/30/2020	344	45	7	8	N/A
6/30/2020	330	50	23	23	N/A
3/31/2020	320	64	38	38	N/A
12/31/2019	314	43	16	16	N/A
9/30/2019	317	114	121	121	N/A
6/30/2019	375	164	153	153	N/A
3/31/2019	338	206	95	95	N/A
12/31/2018	293	129	745	745	N/A
9/30/2018	1,000	647	674	675	N/A
6/30/2018	890	569	568	569	N/A
3/31/2018	877	463	496	496	N/A
12/31/2017	854	387	-340	-339	N/A
9/30/2017	875	452	N/A	465	N/A
6/30/2017	849	364	N/A	406	N/A
3/31/2017	1,144	607	N/A	763	N/A
12/31/2016	1,135	690	N/A	870	N/A
9/30/2016	330	42	N/A	63	N/A
6/30/2016	330	168	N/A	530	N/A
3/31/2016	502	383	N/A	426	N/A
12/31/2015	507	394	N/A	448	N/A
9/30/2015	511	393	N/A	654	N/A
6/30/2015	724	552	N/A	272	N/A
3/31/2015	231	100	N/A	111	N/A
12/31/2014	229	124	N/A	131	N/A
9/30/2014	234	135	N/A	-59	N/A
6/30/2014	28	-128	N/A	-60	N/A
3/31/2014	34	-116	N/A	-53	N/A
12/31/2013	37	-118	N/A	-47	N/A
9/30/2013	37	-110	N/A	-49	N/A
6/30/2013	36	-106	N/A	-77	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4162's forecast earnings growth (15.9% per year) is above the savings rate (1%).

Earnings vs Market: 4162's earnings (15.9% per year) are forecast to grow slower than the TW market (19.7% per year).

High Growth Earnings: 4162's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4162's revenue (7.6% per year) is forecast to grow slower than the TW market (10.6% per year).

High Growth Revenue: 4162's revenue (7.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4162's Return on Equity is forecast to be high in 3 years time

PharmaEngine Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Price target decreased to NT$107

Consensus revenue estimates increase by 10%

Price target decreased to NT$73.50

Analysts lower revenue estimates to NT$384.0m

Recent updates

PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors

PharmaEngine, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings released: EPS: NT$1.91 (vs NT$2.22 in FY 2022)

New major risk - Revenue and earnings growth

PharmaEngine, Inc., Annual General Meeting, May 24, 2024

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

New minor risk - Share price stability

Investor sentiment improves as stock rises 22%

TFDA Approves PharmaEngine, Inc.'s PEP07 Phase I Clinical Trial for Solid Tumor Cancers

Upcoming dividend of NT$2.00 per share at 2.4% yield

Second quarter 2023 earnings released: EPS: NT$0.52 (vs NT$0.56 in 2Q 2022)

New major risk - Revenue and earnings growth

PharmaEngine, Inc. Announces EMAs Acceptance of Onivyde's Type II Variation Application

New major risk - Dividend sustainability

PharmaEngine, Inc. Announces Approval of Phase 1 Clinical Study of Pep07 by TFDA

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased to NT$107

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Now 20% undervalued

PharmaEngine, Inc. Announces Change of Board of Directors Chairperson

PharmaEngine, Inc. Announces Management Changes, Effective September 1, 2022

Investor sentiment improved over the past week

Upcoming dividend of NT$2.70 per share

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Pharmaengine, Inc. Announces Dividend for 2021,Payment Date of Cash Dividend Distribution Is September 2, 2022

Consensus revenue estimates increase by 10%

Investor sentiment improved over the past week

Pharmaengine, Inc. Approves the Change of the Member of Compensation Committee

Now 25% undervalued

First quarter 2022 earnings: EPS exceeds analyst expectations

Price target decreased to NT$73.50

Less than half of directors are independent

Investor sentiment improved over the past week

PharmaEngine, Inc., Annual General Meeting, May 27, 2022

Now 21% undervalued

Third quarter 2021 earnings released: EPS NT$0.51 (vs NT$0.13 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$1.14 (vs NT$0.099 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.52 (vs NT$0.34 in 1Q 2020)

Would PharmaEngine, Inc. (GTSM:4162) Be Valuable To Income Investors?

Full year 2020 earnings released: EPS NT$4.15 (vs NT$0.29 in FY 2019)

PharmaEngine, Inc., Annual General Meeting, May 31, 2021

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

New 90-day high: NT$66.90

How Much Did PharmaEngine's(GTSM:4162) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day low: NT$48.60

Is PharmaEngine, Inc.'s (GTSM:4162) Stock On A Downtrend As A Result Of Its Poor Financials?

New 90-day low: NT$53.70

Analysts lower revenue estimates to NT$384.0m

We're Not Counting On PharmaEngine (GTSM:4162) To Sustain Its Statutory Profitability

New 90-day low: NT$53.90

Revenue and earnings beat expectations

Third quarter 2020 earnings released: EPS NT$0.13

New 90-day low: NT$56.70

New 90-day low: NT$59.10

New 90-day low: NT$64.70

First half earnings released

First half earnings released

Upcoming Dividend of NT$0.50 Per Share

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies